MarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042)

Product Name: MarketVIEW: Hepatitis C Virus (HCV) vaccines
Description: Global vaccine commercial opportunity assessment
Contents: Executive presentation + 2 forecast models
Therapeutic Area: Novel vaccines
Publication date: February 2013
Catalogue No: VAMV042

Background

Hepatitis C is caused by infection with the Hepatitis C virus (HCV). Transmission is predominately through the blood-to-blood route where persons such as current or former injection drug users, past recipients of blood transfusions or solid organ transplants and chronic hemodialysis patients are examples of risk groups. HCV infection becomes chronic in 75-85% of cases and if left untreated can result in chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that about 3% of the world’s population has been infected with HCV and that some 170 million are chronic carriers at risk.

Pegylated interferons (PEG) and the non-specific antiviral ribavirin (R) have been the mainstay of HCV for many years but with lower success rates for patients infected with HCV genotype 1. Recently directly acting antivirals (DAAs) have been available such as Merck’s boceprevir (Victrelis) and Vertex’s telaprevir (Incivek/Incivo/Telavic). Triple therapy with Incivek and PegIFN/R improves SVR rates in treatment naïve and treatment-experienced patients compared to PegIFN/R alone. Beyond DAAs some companies are investigating HCV therapeutic (TX) and prophylatic (PX) vaccines.

This MarketVIEW product contains two comprehensive MS Excel-based models + summary presentation which forecast the potential commercial value of Hepatitis C Virus (HCV) TX and PX vaccines across major Western1 markets until 2030. The models contain value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups. The product also includes an in depth review of latest HCV epidemiological trends, developments in new antivirals and immunological based treatments.

1 US, Canada, Australia, UK, France, Italy, Germany, Spain, South Korea, Japan and Australia
Methodology

VacZine Analytics has closely monitored all significant source material pertaining Hepatitis C Virus (HCV) epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:
Published February 2013 (CAT No: VAMV042)

****This product is composed of two forecast models and a summary presentation

Author’s note
Executive Summary
Commercial model: major outputs
HCV TX vaccines: revenues ($m) by scenario
HCV TX vaccines: revenues ($m) by region
HCV PX vaccines: revenues ($m) by scenario
HCV PX vaccines: revenues ($m) by region
Chronically infected HCV population (000s), by region, 2010-2030
Treated patients (000s), any antiviral therapy (all genotypes), by region, 2010-2030
Treated patients (000s), any antiviral therapy (genotype 1), by region, 2010-2030
Commercial model: key assumptions
The role of HCV TX vaccine
The role of HCV PX vaccine
Key inputs: TX vaccine
Key inputs: PX vaccine
Overview of modelling strategy: TX vaccine
Pricing: TX vaccine
Overview of modelling strategy: PX vaccine
Pricing: PX vaccine
Epidemiology inputs: HCV prevalence
Epidemiology inputs: HCV populations by genotype
Epidemiology inputs: Estimated HCV populations by genotype, 2010
Epidemiology inputs: Injecting drug users
Epidemiology inputs: Estimated treatment rates (% of chronically infected HCV population)
HCV epidemiology summary
US: epidemiology
Europe: epidemiology
Canada: epidemiology
Japan, South Korea, Australia: epidemiology
HCV genotype distribution
Current HCV treatments – review of latest clinical data
Future HCV therapies
HCV vaccine pipeline
Okairos (TerCvax and ProCvax)
Continued........

Globeimmune (GI-5005)
ChronTech (ChronVac-C)
Transgene (TG4040)
Further methodology
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~75 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model TX vaccine (MS Excel-based)

Title sheet
CHARTS – VALUE
CHARTS – VOLUME
CHARTS – Epi
Value
Volume
Epi
Country worksheets ➔
US
Canada
Australia
France
Germany
Italy
Spain
UK
Other Europe
Japan
South Korea
Australia
Source material ➔
Total population
15-64 yrs population
TX vaccine price summary
HCV prevalence
Genotype (% distribution)
Genotype prevalence (number)
IDUs
Treatment rates
HCV cases US
HCV cases UK
HCV cases Germany
HCV cases by risk group
Incivek sales
Clinical trials
Treatment pathway
Back page
Continued........

**Worksheets = 40 interconnected**

**Contents – Vaccine demand model PX vaccine (MS Excel-based)**

- Title sheet
- CHARTS – VALUE
- CHARTS – VOLUME
- Value
- Volume
- Epi
- Country worksheets ➔
- US
- Canada
- Australia
- France
- Germany
- Italy
- Spain
- UK
- Other Europe
- Japan
- South Korea
- Australia
- Source material ➔
- Total population
- 15-64 yrs population
- IDUs
- Vaccine price summary
- Back page

**Worksheets = 40 interconnected**
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $9995.00/ GBP £6245.00* (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
# - indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
31. Worth the Wait? Should chronic hepatitis C patients be treated now or wait for promising therapies? AGA Perspectives. Vol. 8 No. 3. June/July 2012

TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009